ApoGlyx
Aarhus, DK · Founded 2015 · 4 employees on LinkedIn · 2 known investors
Find your way into ApoGlyx
1 people in our graph share verified history with the ApoGlyx team — schools, employers, funds. One of them is your warm intro.
ApoGlyx develops small-molecule aquaporin-9 inhibitors to treat severe inflammatory and metabolic diseases, including acute pancreatitis and diabetes. The company progresses its lead candidate RG210179 through clinical development and collaborates with academic institutions on drug discovery and validation.
Founders & leadership
ApoGlyx was founded in 2015 by Michael Rützler and Søren Nielsen.
MR
Michael RützlerinChief Executive Officer & Co-founderMichael Rützler is CEO and co-founder of ApoGlyx AB, a Lund-based company developing aquaporin inhibitors for metabolic and inflammatory diseases. He founded the company based on his academic research on aquaporin channel function and the discovery of aquaporin inhibitors.
SN
Søren NielsenCo-founder
Investors · 2
In the news
Frequently asked questions
- What does ApoGlyx do?
- ApoGlyx develops small-molecule aquaporin-9 inhibitors to treat severe inflammatory and metabolic diseases, including acute pancreatitis and diabetes. The company progresses its lead candidate RG210179 through clinical development and collaborates with academic institutions on drug discovery and validation.
- Who founded ApoGlyx?
- ApoGlyx was founded by Michael Rützler, Søren Nielsen in 2015.
- Who are ApoGlyx's investors?
- ApoGlyx's investors include LU Innovation, Almi Invest.
- Where is ApoGlyx headquartered?
- ApoGlyx is headquartered in Aarhus, DK.